Perinatal Outcomes in Early and Late Gestational Diabetes Mellitus After Treatment From 24-28 Weeks' Gestation: A TOBOGM Secondary Analysis.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
05
09
2023
accepted:
30
12
2023
medline:
29
2
2024
pubmed:
29
2
2024
entrez:
29
2
2024
Statut:
aheadofprint
Résumé
In most gestational diabetes mellitus (GDM) studies, cohorts have included women combined into study populations without regard to whether hyperglycemia was present earlier in pregnancy. In this study we sought to compare perinatal outcomes between groups: women with early GDM (EGDM group: diagnosis before 20 weeks but no treatment until 24-28 weeks if GDM still present), with late GDM (LGDM group: present only at 24-28 weeks), and with normoglycemia at 24-28 weeks (control subjects). This is a secondary analysis of a randomized controlled treatment trial where we studied, among women with risk factors, early (<20 weeks' gestation) GDM defined according to World Health Organization 2013 criteria. Those receiving early treatment for GDM treatment were excluded. GDM was treated if present at 24-28 weeks. The primary outcome was a composite of birth before 37 weeks' gestation, birth weight ≥4,500 g, birth trauma, neonatal respiratory distress, phototherapy, stillbirth/neonatal death, and shoulder dystocia. Comparisons included adjustment for age, ethnicity, BMI, site, smoking, primigravity, and education. Women with EGDM (n = 254) and LGDM (n = 467) had shorter pregnancy duration than control subjects (n = 2,339). BMI was lowest with LGDM. The composite was increased with EGDM (odds ratio [OR] 1.59, 95% CI 1.18-2.12)) but not LGDM (OR 1.19, 95% CI 0.94-1.50). Induction of labor was higher in both GDM groups. In comparisons with control subjects there were higher birth centile, higher preterm birth rate, and higher rate of neonatal jaundice for the EGDM group (but not the LGDM group). The greatest need for insulin and/or metformin was with EGDM. Adverse perinatal outcomes were increased with EGDM despite treatment from 24-28 weeks' gestation, suggesting the need to initiate treatment early, and more aggressively, to reduce the effects of exposure to the more severe maternal hyperglycemia from early pregnancy.
Identifiants
pubmed: 38421672
pii: 154301
doi: 10.2337/dc23-1667
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : South Western Sydney Local Health District Academic Unit
Organisme : Medical Scientific Fund of the Mayor of Vienna
ID : project numbers 15205 and 23026
Organisme : National Health and Medical Research Council
ID : 1104231
Organisme : Region Örebro Research Committee
ID : 15205
Investigateurs
David Simmons
(D)
N Wah Cheung
(NW)
Jincy Immanuel
(J)
William M Hague
(WM)
Helena Teede
(H)
Christopher J Nolan
(CJ)
Michael J Peek
(MJ)
Jeff R Flack
(JR)
Mark McLean
(M)
Vincent Wong
(V)
Emily Hibbert
(E)
Emily Gianatti
(E)
Arianne Sweeting
(A)
Suzette Coat
(S)
Raiyomand Dalal
(R)
Georgia Soldatos
(G)
Suja Padmanabhan
(S)
Rohit Rajagopal
(R)
Victoria Rudland
(V)
Jürgen Harreiter
(J)
Alexandra Kautzky-Willer
(A)
Herbert Kiss
(H)
Helena Backman
(H)
Erik Schwarcz
(E)
Glynis Ross
(G)
Viswanathan Mohan
(V)
Ranjit Mohan Anjana
(R)
Uma Ram
(U)
Informations de copyright
© 2024 by the American Diabetes Association.